Event to be held in Washington D.C. and will feature Sen. Charles E. Schumer (D-NY) and Families from around the nation who have been impacted by sepsis.
bioMérieux - First-Half 2015 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 28 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2015. The Statutory Auditors had performed a review of the financial statements.
bioMérieux Receives Proclamations for Strike Out Sepsis Day to Help Save Lives Through Greater Awareness of this Deadly Syndrome
Global healthcare leader educates public about sepsis dangers through Strike Out Sepsis events, webinars, grand rounds and Faces of Sepsis survivor stories during Sepsis Awareness Month
bioMérieux receives FDA 510(k) clearance for VIDAS® 3, the new generation of VIDAS®
Innovative VIDAS® immunoassays system designed to answer clinical laboratories needs for automation, traceability, quality and optimized workflow
bioMérieux - First-Half 2015 Business Review
Strong growth in business €933 million in sales Up 19.5% as reported Up 8.1% like-for-like
In the U.S., bioMérieux Introduces New Lyme Disease Diagnostic Tests
New VIDAS® Lyme Assays Provide Differential Detection and Allow Classification of the Infection
bioMérieux 2014 Annual Report
2014 has been an important and decisive year for bioMérieux in more ways than one.
bioMérieux Honored to Participate in the White House Forum on Antibiotic Stewardship
First White House forum to coordinate solutions to address growing public health crisis of antibiotic and antimicrobial resistance
bioMérieux Launches My Role Matters Initiative to Support the fight against Antimicrobial Resistance
New Campaign echoes U.S Administration’s National Strategy for Combating Antibiotic-Resistant Bacteria